LLY

1,027.02

+2.32%↑

JNJ

195

+0.45%↑

ABBV

238.33

+3.94%↑

UNH

335.06

-0.83%↓

AZN

88.94

+0.33%↑

LLY

1,027.02

+2.32%↑

JNJ

195

+0.45%↑

ABBV

238.33

+3.94%↑

UNH

335.06

-0.83%↓

AZN

88.94

+0.33%↑

LLY

1,027.02

+2.32%↑

JNJ

195

+0.45%↑

ABBV

238.33

+3.94%↑

UNH

335.06

-0.83%↓

AZN

88.94

+0.33%↑

LLY

1,027.02

+2.32%↑

JNJ

195

+0.45%↑

ABBV

238.33

+3.94%↑

UNH

335.06

-0.83%↓

AZN

88.94

+0.33%↑

LLY

1,027.02

+2.32%↑

JNJ

195

+0.45%↑

ABBV

238.33

+3.94%↑

UNH

335.06

-0.83%↓

AZN

88.94

+0.33%↑

Search

Simulations Plus Inc

Avatud

SektorTervishoid

17.1 -1.38

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.91

Max

17.6

Põhinäitajad

By Trading Economics

Sissetulek

-70M

-67M

Müük

-2.1M

20M

P/E

Sektori keskmine

48.528

105.69

Dividenditootlus

0.48

Kasumimarginaal

-330.585

Töötajad

243

EBITDA

327K

5.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-7.67% downside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.37%

Järgmine tulemuste avaldamine

1. dets 2025

Turustatistika

By TradingEconomics

Turukapital

-5.6M

346M

Eelmine avamishind

18.48

Eelmine sulgemishind

17.1

Uudiste sentiment

By Acuity

50%

50%

182 / 374 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2025, 21:55 UTC

Tulu

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12. nov 2025, 21:34 UTC

Tulu

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12. nov 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12. nov 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12. nov 2025, 22:30 UTC

Market Talk
Tulu

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12. nov 2025, 22:18 UTC

Tulu

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12. nov 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12. nov 2025, 22:05 UTC

Tulu

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Adj EPS 48c >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Rev $884.4M >PAAS

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q EPS 45c >PAAS

12. nov 2025, 22:03 UTC

Tulu

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Net C$1.8B >MFC

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q EPS C$1.02 >MFC

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12. nov 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12. nov 2025, 21:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

12. nov 2025, 21:49 UTC

Tulu

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12. nov 2025, 21:48 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12. nov 2025, 21:40 UTC

Tulu

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

-7.67% langus

12 kuu keskmine prognoos

Keskmine 16 USD  -7.67%

Kõrge 16 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

182 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat